Tamoxifen

Generic Name
Tamoxifen
Brand Names
Soltamox
Drug Type
Small Molecule
Chemical Formula
C26H29NO
CAS Number
10540-29-1
Unique Ingredient Identifier
094ZI81Y45
Background

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...

Indication

Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.

Associated Conditions
Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
Associated Therapies
Ovulation induction therapy
Clinical Trials
Related News

ATAC - Bone Density Sub-Protocol

Phase 3
Completed
Conditions
Bone Density
Interventions
Drug: Anastrozole
Drug: Tamoxifen
First Posted Date
2008-11-04
Last Posted Date
2009-04-27
Lead Sponsor
AstraZeneca
Target Recruit Count
308
Registration Number
NCT00784940

Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

Phase 1
Completed
Conditions
Chronic Hepatitis C
Interventions
Drug: tamoxifen
First Posted Date
2008-09-09
Last Posted Date
2010-03-09
Lead Sponsor
Bader, Ted, M.D.
Target Recruit Count
18
Registration Number
NCT00749138
Locations
🇺🇸

VA Hospital, Oklahoma City, Oklahoma, United States

Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer

First Posted Date
2008-08-20
Last Posted Date
2021-01-22
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
250
Registration Number
NCT00738777
Locations
🇳🇱

UMC St. Radboud, Nijmegen, Netherlands

🇳🇱

NKI-AVL, Amsterdam, Netherlands

🇳🇱

Medisch Centrum Haaglanden, den Haag, ZH, Netherlands

and more 1 locations

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

First Posted Date
2008-08-06
Last Posted Date
2018-06-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
93
Registration Number
NCT00728949
Locations
🇺🇸

ImClone Investigational Site, Nashville, Tennessee, United States

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Phase 2
Completed
Conditions
Urinary Bladder Neoplasms
Interventions
Drug: Tamoxifen
First Posted Date
2008-07-08
Last Posted Date
2022-01-24
Lead Sponsor
Seth Lerner
Target Recruit Count
28
Registration Number
NCT00710970
Locations
🇮🇹

San Camillo and Forlanini Hospitals, Rome, Italy

🇺🇸

Baylor College Of Medicine, Houston, Texas, United States

Cognition in the Study of Tamoxifen and Raloxifene

Phase 3
Completed
Conditions
Aging
Cognition
Interventions
Drug: tamoxifen
Drug: raloxifene
First Posted Date
2008-05-30
Last Posted Date
2018-09-12
Lead Sponsor
Wake Forest University
Target Recruit Count
1498
Registration Number
NCT00687102
Locations
🇺🇸

The Harry and Jeanette Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States

🇺🇸

CCOP Columbus, Columbus, Ohio, United States

🇺🇸

Montana Cancer Consortium, Billings, Montana, United States

and more 131 locations

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

First Posted Date
2008-04-16
Last Posted Date
2016-07-25
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
86
Registration Number
NCT00659373
Locations
🇺🇸

Front Range Cancer Specialists, Fort Collins, Colorado, United States

🇺🇸

New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States

🇺🇸

Batte Cancer Center at Northeast Medical Center, Concord, North Carolina, United States

and more 12 locations

Casodex - Nolvadex Combination

Phase 2
Completed
Conditions
Gynaecomastia
Prostate Cancer
Interventions
Drug: Casodex
Drug: Tamoxifen
First Posted Date
2008-03-18
Last Posted Date
2011-01-24
Lead Sponsor
AstraZeneca
Registration Number
NCT00637871

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

First Posted Date
2008-01-31
Last Posted Date
2012-09-06
Lead Sponsor
AstraZeneca
Target Recruit Count
197
Registration Number
NCT00605267
Locations
🇯🇵

Research Site, Osaka, Japan

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

First Posted Date
2008-01-11
Last Posted Date
2017-08-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT00590785
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy